Known targets — ChEMBL curated mechanism
ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Luteolinidin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD38 | P28907 | 11/20 | 0.97 |
| ▸ | GLO1 | Q04760 | 5/20 | 0.63 |
| ▸ | SNCA | P37840 | 3/20 | 0.63 |
| ▸ | DPP4 | P27487 | 3/20 | 0.63 |
| ▸ | F2 | P00734 | 1/20 | 0.60 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.60 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.60 |
| ▸ | OR51E2 | Q9H255 | 2/20 | 0.50 |
| ▸ | EGFR | P00533 | 2/20 | 0.46 |
| ▸ | KDR | P35968 | 2/20 | 0.46 |
| ▸ | EP300 | Q09472 | 2/20 | 0.46 |
| ▸ | CREBBP | Q92793 | 2/20 | 0.46 |
| ▸ | APP | P05067 | 2/20 | 0.41 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.40 |
| ▸ | MAOA | P21397 | 1/20 | 0.38 |
| ▸ | QDPR | P09417 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Luteolinidin SCHEMBL30159678 | 0.98 | CD38 (1.00) | CD38GLO1SNCADPP4F2 | |
| Luteolinidin SCHEMBL676808 | 0.98 | CD38 (1.00) | CD38GLO1SNCADPP4F2 | |
| SCHEMBL7045086 | 0.87 | CD38 (0.79) | CD38GLO1SNCADPP4F2 | |
| Hydrochloric Acid SCHEMBL29413086 | 0.87 | CD38 (0.73) | CD38GLO1SNCADPP4F2 | |
| Hydrochloric Acid SCHEMBL29392598 | 0.87 | CD38 (0.73) | CD38GLO1SNCADPP4F2 | |
| Hydrochloric Acid SCHEMBL1366891 | 0.87 | CD38 (0.73) | CD38GLO1SNCADPP4F2 | |
| Hydrochloric Acid SCHEMBL6131747 | 0.85 | CD38 (0.71) | CD38GLO1SNCADPP4F2 | |
| Hydrochloric Acid SCHEMBL11317960 | 0.85 | CD38 (0.71) | CD38GLO1SNCADPP4F2 | |
| SCHEMBL5692415 | 0.85 | CD38 (0.76) | CD38GLO1SNCADPP4F2 | |
| SCHEMBL6131745 | 0.83 | CD38 (0.73) | CD38GLO1SNCADPP4F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 942 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260090969-A1 | COMPOSITIONS THAT PROTECT CELLS FROM OXIDATIVE AND MITOCHONDRIAL STRESS | Nuchido Limited (GB) | 2026-04-02 | — | — | US | claimed |
| EP-4622686-A1 | SPRAY PATCH COMPOSITION, PROCESS FOR PREPARING IT AND KIT | Fondazione Istituto Italiano di Tecnologia (IT) | 2025-10-01 | — | — | EP | claimed |
| WO-2025093707-A1 | METHOD FOR SUPPRESSING CAR-T CELLS UNRESPONSIVENESS FOR IMPROVING CANCER IMMUNOTHERAPY | Université de Lausanne (CH) | 2025-05-08 | — | — | WO | claimed |
| US-20250064094-A1 | COMPOSITIONS FOR FOOD COLORING AND ANTIOXIDANT SUPPLEMENTATION DERIVED FROM SORGHUM | RedLeaf Biologics, Inc. (US) | 2025-02-27 | — | — | US | claimed |
| EP-4472625-A1 | COMPOSITIONS FOR FOOD COLORING AND ANTIOXIDANT SUPPLEMENTATION DERIVED FROM SORGHUM | Redleaf Biologics, Inc. (US) | 2024-12-11 | — | — | EP | claimed |
| WO-2024248183-A1 | HAIR-PROTECTING COMPOSITION AND HAIR CARE PRODUCT COMPRISING SAME | 주식회사 모다바이오 | 2024-12-05 | — | — | WO | claimed |
| EP-4426338-A2 | CD38 COMPOSITIONS AND METHODS FOR IMMUNOTHERAPY | Intellia Therapeutics, Inc. (US) | 2024-09-11 | — | — | EP | claimed |
| WO-2024110911-A1 | SPRAY PATCH COMPOSITION, PROCESS FOR PREPARING IT AND KIT | FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA (IT) | 2024-05-30 | — | — | WO | claimed |
| US-20230355769-A1 | COMPOSITIONS, CONTAINERS, AND METHODS RELATED TO FLAVYLIUM EXCIPIENTS | Natural Extraction Systems, LLC (US) | 2023-11-09 | — | — | US | claimed |
| US-20230338331-A1 | COMPOSITIONS, CONTAINERS, AND METHODS RELATED TO FLAVYLIUM EXCIPIENTS | Natural Extraction Systems, LLC (US) | 2023-10-26 | — | — | US | claimed |
| EP-1172090-B1 | Skin dyeing compositions comprising dihydroxyacetone and a flavylium salt non substituted in position 3 | OREAL (FR) | 2005-03-09 | — | — | EP | claimed |
| EP-1172093-B1 | Compositions for coloring the skin containing flavylium salt compounds unsubstituted in position 3 and an organomodified silicone | OREAL (FR) | 2004-12-01 | — | — | EP | claimed |
| WO-2004100685-A1 | MOLD INHIBITOR INTEGRATED WITHIN A MATRIX AND METHOD OF MAKING SAME | MARKHAM JOSEPH P (US) | 2004-11-25 | — | — | WO | claimed |
| US-20040223999-A1 | Mold inhibitor integrated within a matrix and method of making same | MARKHAM JOSEPH P (US) | 2004-11-11 | — | — | US | claimed |
| EP-1172092-B1 | Compositions for coloring the skin containing at least one UV filter and flavylium salt compounds unsubstituted in position 3 | OREAL (FR) | 2004-09-15 | — | — | EP | claimed |
| WO-2002024212-A1 | CHOLESTEROL IN BLOOD-LOWERING COMPOSITION AND ITS COMPLEX, AND METHOD FOR PREPARING THEM | ULTIMATE LIFE TECHNOLOGY CO., LTD. (KR) | 2002-03-28 | — | — | WO | claimed |
| WO-1997041137-A1 | USE OF ANTHOCYANIDIN AND ANTHOCYANIDIN DERIVATIVES | UNIFOB (NO) | 1997-11-06 | — | — | WO | claimed |
| EP-0785790-A1 | USE OF ANTHOCYANIDIN AND DERIVATIVES FOR TREATMENT OF RETROVIRAL INFECTIONS | UNIFOB STIFTELSEN UNIVERSITETSFORSKNING BERGEN (NO) | 1997-07-30 | — | — | EP | claimed |
| WO-1996011692-A9 | USE OF ANTHOCYANIDIN AND DERIVATIVES FOR TREATMENT OF RETROVIRAL INFECTIONS | — | 1996-06-20 | — | — | WO | claimed |
| WO-1996011692-A1 | USE OF ANTHOCYANIDIN AND DERIVATIVES FOR TREATMENT OF RETROVIRAL INFECTIONS | UNIFOB STIFTELSEN UNIVERSITETSFORSKNING BERGEN (NO) | 1996-04-25 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260090969-A1 | COMPOSITIONS THAT PROTECT CELLS FROM OXIDATIVE AND MITOCHONDRIAL STRESS | NLN, TFAM, CYP27B1 | CD38 974/4885GLO1 2231/4885SNCA 1789/4885 |
| US-20230355769-A1 | COMPOSITIONS, CONTAINERS, AND METHODS RELATED TO FLAVYLIUM EXCIPIENTS | CNR2, CNR1, UGT8 | CD38 2308/4885GLO1 2357/4885SNCA 958/4885 |
| US-20230338331-A1 | COMPOSITIONS, CONTAINERS, AND METHODS RELATED TO FLAVYLIUM EXCIPIENTS | CNR2, CNR1, UGT8 | CD38 2308/4885GLO1 2357/4885SNCA 958/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.